
Cardiex Ltd
ASX:CDX

Intrinsic Value
CardieX Ltd. is engaged in the designing, manufacturing, and marketing of medical devices for use in cardiovascular health management. [ Read More ]
The intrinsic value of one
CDX
stock under the Base Case scenario is
0.018
AUD.
Compared to the current market price of 0.135 AUD,
Cardiex Ltd
is
Overvalued by 87%.

Valuation History
Cardiex Ltd

Intrinsic Value History...
Our system is conducting in-depth analyses to map out the stock's valuation journey. Thank you for waiting.
Fundamental Analysis
Balance Sheet Decomposition
Cardiex Ltd
Current Assets | 11.6m |
Cash & Short-Term Investments | 716k |
Receivables | 7.8m |
Other Current Assets | 3.1m |
Non-Current Assets | 2.7m |
Long-Term Investments | 510k |
PP&E | 1.5m |
Intangibles | 633k |
Other Non-Current Assets | 78.6k |
Current Liabilities | 14.8m |
Accounts Payable | 7.5m |
Accrued Liabilities | 489k |
Short-Term Debt | 1.5m |
Other Current Liabilities | 5.4m |
Non-Current Liabilities | 489k |
Long-Term Debt | 483k |
Other Non-Current Liabilities | 6.2k |
CDX Profitability Score
Profitability Due Diligence
Cardiex Ltd's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

Score
Cardiex Ltd's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
CDX Solvency Score
Solvency Due Diligence
Cardiex Ltd's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Score
Cardiex Ltd's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CDX Price Targets Summary
Cardiex Ltd
Shareholder Return
CDX Price
Cardiex Ltd
Average Annual Return | 33.16% |
Standard Deviation of Annual Returns | 61.85% |
Max Drawdown | -88% |
Market Capitalization | 19.4m AUD |
Shares Outstanding | 143 683 524 |
Percentage of Shares Shorted |
N/A
|
Company Profile


Country
Industry
Market Cap
Dividend Yield
Description
CardieX Ltd. is engaged in the designing, manufacturing, and marketing of medical devices for use in cardiovascular health management. The company is headquartered in Sydney, New South Wales. The company went IPO on 2005-11-09. The firm is focused on designing, manufacturing and marketing medical devices for use in cardiovascular health management. The company operates through its subsidiaries, including ATCOR and CONNEQT. The firm's ATCOR division provides medical devices for measuring arterial stiffness and central blood pressure waveforms based on its FDA-cleared and patented SphygmoCor technology. Under the ATCOR.X brand, the Company also develops and licenses its Arty platform consisting of physiological and health analytics for wearable devices. The firm's digital platform, ArtyNet, is a connected software as a service ecosystem providing physicians with a telehealth solution for remotely managing patients' health. CONNEQT develops and markets consumer wearable and home health devices focused on heart health and its patented fitness and wellness parameters.
Contact
IPO
Employees
Officers
The intrinsic value of one
CDX
stock under the Base Case scenario is
0.018
AUD.
Compared to the current market price of 0.135 AUD,
Cardiex Ltd
is
Overvalued by 87%.